title: Management of pulmonary hypertension due to heart failure with preserved ejection fraction.
abstract: Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.
authors.affiliation: Cardiovascular Institute, Allegheny General Hospital, 320 East North Ave, 16th floor, South Tower, Pittsburgh, PA, 15212, USA, mkanwar@wpahs.org.
authors.forename: Manreet
authors.initials: M
authors.lastname: Kanwar
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Tedford
authors.forename: Richa
authors.initials: R
authors.lastname: Agarwal
authors.forename: Megan M
authors.initials: MM
authors.lastname: Clarke
authors.forename: Claire
authors.initials: C
authors.lastname: Walter
authors.forename: George
authors.initials: G
authors.lastname: Sokos
authors.forename: Srinivas
authors.initials: S
authors.lastname: Murali
authors.forename: Raymond L
authors.initials: RL
authors.lastname: Benza
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000150:complications*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D017410:Practice Guidelines as Topic; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology*